Sana Biotechnology Obtains a Non-Exclusive License to CRISPR Cas12b Gene Editing Technology from Beam Therapeutics to Enable Engineered Cell Programs
Agreement combines Beam’s gene editing technology with Sana’s ex vivo platform SEATTLE, Oct. 19, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology,...